Saturday 17 October 2026
Export CAMP’s income statement to Excel — free account
CAMP4 Therapeutics Corporation
CAMP Healthcare Biotechnology
CAMP4 Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, up 436.5% from fiscal 2024. In the quarter to June 2026, revenue grew 18.8%, EPS grew 6.45% and free cash flow fell 23.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.17
0.28
−8.12%
Follow CAMP
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (545.85%) | (209.28%) | (145.07%) | 106.47% |
+8 more TTM periods Free account |
|
| (148.23%) | (102.60%) | (82.00%) | (99.11%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(147.45%) | (98.63%) | (79.67%) | (73.45%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.50) | (0.45) | (0.98) | (1.75) | |
Free Cash Flow |
(28.68) | (26.25) | (29.80) | (47.64) | |
Capital Expenditures |
(0.09) | — | (0.24) | (0.51) | |
| Other line items | |||||
Cash ROIC |
(33.19%) | (20.06%) | (18.79%) | (35.56%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
917.69% | 971.43% | 1,092.11% | 1,138.03% | |
Selling, General and Administrative Expense of Revenue |
424.81% | 451.19% | 496.20% | 494.03% | |
Share Based Compensation of Revenue |
131.36% | 117.16% | 114.29% | 104.11% | |
Operating CF/Net income |
0.27 | 0.30 | 0.37 | 0.88 | |
Depreciation/Fixed assets |
0.99 | 0.90 | 0.70 | 0.58 | |
Capex/Depreciation |
(0.05) | 0.00 | (0.15) | (0.30) | |
Revenue per Share |
0.07 | 0.07 | 0.12 | 0.13 | |
Operating CF per Share |
(0.49) | (0.45) | (0.97) | (1.73) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.02) | |
Capex to Sales |
0.02 | 0.00 | 0.07 | 0.14 |
Columns are period end dates